[PDF][PDF] Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

AP Durbin, RA Karron, W Sun… - The American journal …, 2001 - researchgate.net
AP Durbin, RA Karron, W Sun, DW Vaughn, MJ Reynolds, JR Perreault, B Thumar, R Men…
The American journal of tropical medicine and hygiene, 2001researchgate.net
The recombinant dengue virus type-4 vaccine candidate 2A30 was attenuated in rhesus
monkeys due to an engineered 30-nucleotide deletion in the 3-untranslated region of the
viral genome. A clinical trial to evaluate the safety and immunogenicity of a single dose of
2A30 was conducted with 20 adult human volunteers. The vaccine candidate was well
tolerated and did not cause systemic illness in any of the 20 volunteers. Viremia was
detectable in 14 volunteers at a mean level of 1.6 log10 plaque-forming units/ml of serum …
Abstract
The recombinant dengue virus type-4 vaccine candidate 2A30 was attenuated in rhesus monkeys due to an engineered 30-nucleotide deletion in the 3-untranslated region of the viral genome. A clinical trial to evaluate the safety and immunogenicity of a single dose of 2A30 was conducted with 20 adult human volunteers. The vaccine candidate was well tolerated and did not cause systemic illness in any of the 20 volunteers. Viremia was detectable in 14 volunteers at a mean level of 1.6 log10 plaque-forming units/ml of serum, although all 20 volunteers seroconverted with a seven-fold or greater increase in serum neutralizing antibody titer on day 28 post-vaccination (mean titer 1: 580). A mild, asymptomatic, macular rash developed in 10 volunteers, and a transient elevation in the serum level of alanine aminotransferase was noted in five volunteers. The low level of reactogenicity and high degree of immunogenicity of this vaccine candidate warrant its further evaluation and its use to create chimeric vaccine viruses expressing the structural genes of dengue virus types 1, 2, and 3.
researchgate.net